Table 2.
Competing risks hazard ratios for the association between diabetes and prostate cancer–specific mortality in all men and stratified by obesity status
| Diabetes status and duration | All men |
Obese men |
Nonobese men |
P interaction c | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of events/No. of men | HR (95% CI) | P | No. of events/No. of men | HR (95% CI) | P | No. of events/No. of men | HR (95% CI) | P | ||
| Age-adjusted | ||||||||||
| Diabetes, No | 78/3733 | Referent | — | 18/1073 | Referent | — | 60/2660 | Referent | — | — |
| Diabetes, Yes | 24/955 | 1.34 (0.85 to 2.12) | .21 | 17/487 | 2.25 (1.15 to 4.40) | .02 | 7/468 | 0.71 (0.32 to 1.57) | .40 | .02 |
| Duration of diabetes, y | 24/955 | 1.04 (0.99 to 1.09) | .10 | 17/487 | 1.01 (0.94 to 1.08) | .84 | 7/468 | 1.09 (1.03 to 1.14) | <.001 | .51 |
| Duration of diabetes, ya | 23/917 | 1.07 (1.00 to 1.15) | .06 | 17/468 | 1.04 (0.95 to 1.13) | .45 | 6/449 | 1.17 (1.05 to 1.29) | .003 | .47 |
| Multivariableb | ||||||||||
| Diabetes, No | 78/3733 | Referent | — | 18/1073 | Referent | — | 60/2660 | Referent | — | — |
| Diabetes, Yes | 24/955 | 1.38 (0.86 to 2.24) | .18 | 17/487 | 3.06 (1.40 to 6.69) | .005 | 7/468 | 0.65 (0.28 to 1.49) | .31 | .005 |
| Duration of diabetes, y | 24/955 | 1.03 (0.98 to 1.09) | .24 | 17/487 | 0.99 (0.91 to 1.07) | .72 | 7/468 | 1.11 (1.02 to 1.21) | .02 | .89 |
| Duration of diabetes, ya | 23/917 | 1.07 (1.00 to 1.15) | .07 | 17/468 | 1.04 (0.93 to 1.15) | .54 | 6/449 | 1.21 (0.99 to 1.47) | .06 | .91 |
a
Men with outlying values > [Q3 + (1.5*IQR)] of duration of diabetes were excluded. CI = confidence interval; HR = hazard ratio.
b
Adjusted for age, race, log-transformed body mass index, preoperative prostate-specific antigen (log-transformed), year of surgery, surgical center, clinical stage, margins status, extracapsular extension, seminal vesicle invasion, lymph node status, and pathological grade group.
c
Two-sided P value for interaction between diabetes and obesity.